Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, JiangsuPeople's Republic of China.
Zhenjiang Clinical Research Center of Hematology, Zhenjiang, Jiangsu, People's Republic of China.
Aging (Albany NY). 2020 Jun 26;12(14):14677-14690. doi: 10.18632/aging.103520.
DNA methyltransferases () by regulating DNA methylation play crucial roles in the progression of hematologic malignancies, especially for acute myeloid leukemia (AML). Accumulating investigations have identified the high incidence of mutation in AML, and it is correlated with poor prognosis. Although a few studies have shown the expression of and their clinical significance in AML, the results remain to be discussed. Herein, we systemically analyzed the expression and their relationship with clinic-pathological features and prognosis in AML patients. expression especially for / was closely associated with AML among various human cancers. expression was increased in AML patients, whereas expression was decreased. Significant associations between / expression and clinic-pathological features/gene mutations were observed. Kaplan-Meier analysis showed that expression was associated with better overall survival (OS) and leukemia-free survival (LFS) among whole-cohort AML, and independently affected OS determined by Cox repression multivariate analysis. Notably, patients that received hematopoietic stem cell transplantation (HSCT) showed significantly better OS and LFS in lower-expressed groups, whereas patients in higher-expressed groups did not. By bioinformatics analysis, expression was found to be positively correlated with several leukemia-associated genes/microRNAs, and was identified as direct targets of and in AML. Collectively, our study demonstrated that / showed significant expression differences in AML. expression acted as a potential prognostic biomarker and may guide treatment choice between chemotherapy and HSCT in AML.
DNA 甲基转移酶 () 通过调节 DNA 甲基化在血液恶性肿瘤的进展中发挥关键作用，特别是在急性髓系白血病 (AML) 中。越来越多的研究已经确定了 AML 中 突变的高发率，并且与不良预后相关。尽管一些研究已经显示了 在 AML 中的表达及其临床意义，但结果仍有待讨论。在此，我们系统地分析了 AML 患者中 表达及其与临床病理特征和预后的关系。 表达，尤其是 /，在各种人类癌症中与 AML 密切相关。AML 患者中 表达增加，而 表达降低。/ 表达与临床病理特征/基因突变之间存在显著相关性。Kaplan-Meier 分析表明，在整个 AML 队列中， 表达与总生存 (OS) 和无白血病生存 (LFS) 相关，并且通过 Cox 比例风险多变量分析独立影响 OS。值得注意的是，接受造血干细胞移植 (HSCT) 的患者在 低表达组中具有显著更好的 OS 和 LFS，而在 高表达组中则没有。通过生物信息学分析，发现 表达与几个与白血病相关的基因/ microRNAs 呈正相关，并且在 AML 中被鉴定为 和 的直接靶标。总的来说，我们的研究表明，/ 在 AML 中表现出显著的表达差异。 表达作为一种潜在的预后生物标志物，可能指导 AML 中化疗和 HSCT 之间的治疗选择。
